8 European Projects Found
Searched on 125080 European Projects
FINISHED
PRIMES: Protein interaction machines in oncogenic EGF receptor signalling (PRIMES)
Start date: Dec 1, 2011, End date: Nov 30, 2016,
"PRIMES focuses on the role of protein interactions to assemble dynamic molecular machines that receive and process information to coordinate cellular responses. PRIMES investigates the following: (i) How do protein interactions contribute to the generation of biological specificity in signalling? (ii) How do pathogenetic perturbations affect protein interaction networks? (iii) How can we exploit ...
Read Project
14
Partners Participants
FINISHED
More Medicines for Tuberculosis (MM4TB)
Start date: Feb 1, 2011, End date: Jul 31, 2016,
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be impleme ...
Read Project
27
Partners Participants
FINISHED
Innovative anti-influenza drugs excluding viral escape (ANTIFLU)
Start date: Jun 1, 2011, End date: May 31, 2016,
ANTIFLU is to develop innovative drugs against influenza virus infections based on a novelconcept that precludes the development of viral resistance and ensures efficacy againstupcoming pandemic influenza strains. Viral replication is known to depend on multiple hostfactors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU willaim at drugs interfering with host-re ...
Read Project
11
Partners Participants
FINISHED
Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases (TARKINAID)
Start date: Jan 1, 2012, End date: Dec 31, 2015,
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant con ...
Read Project
11
Partners Participants
FINISHED
New approaches for the targeted therapy of Non-Small Cell Lung Cancer (LUNGTARGET)
Start date: Jan 1, 2011, End date: Jun 30, 2015,
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival
Read Project
10
Partners Participants
FINISHED
OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma (OPTATIO)
Start date: Jan 1, 2012, End date: Mar 31, 2015,
Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenv ...
Read Project
13
Partners Participants
FINISHED
Exploiting Gram-negative cell division targets in the test tube to obtain anti-microbial compounds (DIVINOCELL)
Start date: Mar 1, 2009, End date: Aug 31, 2013,
The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interactions. It will also design selective assays for screening and will obtain a new class of antimicrobials: compounds to block bacterial division. New medicines to attack Gram-negative pathogens will decrease the burden of infectious disease and have a highly ben ...
Read Project
12
Partners Participants
FINISHED
Novel strategies for the prevention and control of persistent infections (NOPERSIST)
Start date: Jan 1, 2010, End date: Dec 31, 2012,
...nst the persistent infections addresses in this proposal. The four SME members of this consortium with complimentary areas of research and business activities, LIONEX (in TB), Prionics (in ParaTB) , Vichem (in HIV) and IVD (in pig infections) are dedicated to solving the problems of the persistent infections mentioned above by employing novel strategies of product development for diagnosis, preven ...
Read Project
